What concerns, if any, do you have with using Jivi (damoctogog alfa peg) in pediatric patients 7-12 years old, with severe hemophilia A?
Jivi (damoctogog alfa peg) received FDA approval expansion in May 2025, as a result of the Alfa-PROTECT and PROTECT Kids trials.